Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27803045.
- Also identified by DOI 10.1158/1078-0432.CCR-16-2400 and PMC identifier 5215130.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6-8. ©2016 AACRSee related article by Sinnott et al., p. 81.
Medical subject headings
- Gene Expression Regulation, Neoplastic
- Prostatic Neoplasms
- Transcriptome